NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice

INTRODUCTION: In humans, approximately 5% of all cancers are attributable to HPV infection. Prophylactic vaccines can inhibit viral migration and persistence. However, further studies are still required to develop such treatments. To achieve this goal, we designed a therapeutic HPV DNA vaccine encod...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadr-Momtaz, Sahar, Aftabi, Maryam, Behboudi, Emad, Naderi, Malihe, Hashemzadeh-Omran, Anahita, Moradi, Abdolvahab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408056/
https://www.ncbi.nlm.nih.gov/pubmed/37550734
http://dx.doi.org/10.1186/s13104-023-06445-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408056/
https://www.ncbi.nlm.nih.gov/pubmed/37550734
http://dx.doi.org/10.1186/s13104-023-06445-5

Ejemplares similares